

8-13-07

121
9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gans, et al.

Serial No.: 10/825,977

Filed: April 16, 2004

Attorney Docket No.: 01-40326-USC

Examiner: WANG, Shengjun

Group Art Unit: 1617

Title: Compositions and Methods for
Enhancing Corticosteroid Delivery

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(c)(2)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The above-identified Applicant submits herewith a copy of references, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. Form PTO-1449, attached hereto, lists the references of which Applicant is aware, and which may be material to the examination of this application.

While the information cited in this Information Disclosure Statement may be "material" pursuant to 37 C.F.R. § 1.56, the filing of these references should not be construed to be an admission that any patent, publication or other information referred to herein is, or is considered to be, either "prior art" for this invention or otherwise material to the patentability of this invention as defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

It is believed that this Information Disclosure Statement is being filed prior to the mailing date of any final action, a notice of allowance, or an action that otherwise closes prosecution of the application pursuant to 37 C.F.R. §1.97(c)(2).

The fee under 37 C.F.R. §1.97(c)(2) is \$180.00 and is enclosed herewith. In the event that there is any fee due or overpayment credited, the Commissioner is hereby authorized to charge fees and credit overpayment to Deposit Account No. 18-0586.


CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EV 699 483 767 US
Date of Deposit: August 10, 2007

I hereby certify that this paper and/or fee is being deposited with the United States Postal Service, "EXPRESS MAIL – POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.


Franziska Reichstein

(Name of person mailing paper.)




(Signature of person mailing paper.)

Respectfully submitted,



William J. McNichol, Jr.
Registration No. 31,179
REED SMITH LLP
2500 One Liberty Place
1650 Market Street
Philadelphia, PA 19103-7301
(215) 241-5663

Attorney for Applicant



FORM PTO 449 COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 01-40326-USC	SER. NO. 10/825,977
	APPLICANT Gans et al.	
	FILING DATE April 16, 2004	GROUP 1617

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
	AA	U.S. 3,592,930	July 13, 1971	Katz, et al.		July 19, 1968
	AB	U.S. 4,017,615	April 12, 1977	Shastri, et al.		Dec. 11, 1975

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Cite No.	Document Number	Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
	BA					

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
	CA	Barry, B.W. "Dermatological Formulations" New York: Marcel Dekker, Inc. (1983) pp. 264-280
	CB	Beger, et al. "Developing ¹³ C NMR Quantitative Spectrometric Data-Activity Relationship (QSDAR) Models of Steroid binding to the Corticosteroid binding Globulin" Journal of Computer-Aided Molecular Design (2001) Vol. 15, No. 7, pp. 659-669
	CC	Birch, A.J. "Profiles, Pathways and Dreams" To See the Obvious; American Chemical Society, Washington DC(1995), pp. 87-92
	CD	Bledsoe, et al. "Structure and Function of the Glucocorticoid Receptor Ligand Binding Domain" Vitamins and Hormones (2004) Vol. 68, pp. 49-91
	CE	Bowers A., et al. "Synthesis of halogenated steroid hormones – II, 6α-and 6β-fluorotestosterone and 6α-and 6β fluoroprogesterone." Tetrahedron The International Journal of Organic Chemistry (1958) 3, pp. 14-27
	CF	Bowers, et al. "Steroids. CIII. A new class of potent Cortical Hormones, 6α-Fluorocorticoids" The Journal of the American Chemical Society (1958), pp. 4423-4424
	CG	Buchwald, et al. "Soft Glucocorticoid Design: Structural Elements and Physicochemical Parameters determining Receptor-Binding Affinity" Die Pharmazie (2004) Vol. 59, pp. 396-404

CH	Counce, et al. "Fluocinonide: A new Topical Corticosteroid for Psoriasis and other Dermatoses" The Journal of the Louisiana State Medical Society (1972) Vol. 124, No. 10, pp. 365-367
CI	Djerassi C. "The pill, pygmy chimps, and Degas' Horse" New York: Basic Books (1992) pp. 34-48
CJ	Dumas, et al. "The Psoriasis Bio-Assay for Topical Corticosteroid Activity" Acta Dermatovener (Stockholm) (1972) Vol. 52, pp. 43-48
CK	Fieser, et al. "Adrenocortical Hormones" Steroids (1950) Chapter 19, pp. 600-610
CL	Fried, et al. "The Use of Microorganisms in the Synthesis of Steroid Hormones and Hormone Analogues" Recent Progress in Hormone Research (1955) Vol. XI, pp. 149-181
CM	Fried, et al. "Cyclic 16 α , 17 α -Ketals and Acetals of 9 α -Fluoro-16 α -Hydroxy-Cortisol and-Prednisolone" The Journal of the American Chemical Society (1958) Vol. LXXX, pp. 2338-2339
CN	Haleblian J. "Bioassays Used in Development of Topical Dosage Forms" Journal of Pharmaceutical Sciences (1976) Vol. 65, No. 10, pp. 1417-1436
CO	Hammer, et al. "Glucocorticoid Receptor Interactions with Glucocorticoids: Evaluation by Molecular Modeling and Functional Analysis of Glucocorticoid Receptor Mutants" Steroids (2003) Vol. 68, No. 4, pp. 329-339
CP	Hench, et al. "Cortisone – Its Effects of Rheumatoid Arthritis, Rheumatic Fever, and Certain Other Conditions" The Merck Report (1950) pp. 9-14
CQ	Hench, et al. "The Effect of a Hormone of the Adrenal Cortex (17-Hydroxy-11-Dehydrocorticosterone: Compound E) and of Pituitary Adrenocorticotrophic Hormone on Rheumatoid Arthritis" Proceedings of the Staff Meetings of the Mayo Clinic (1949) Vol. 24, No. 8, pp. 182-197
CR	Herzog, et al. "New Antiarthritic Steroids" Science (1955) Vol. 121, p. 176
CS	Hogg, et al. "6-Fluoro Analogues of Steroid Hormones" Chemistry and Industry (1958), pp. 1002-1003
CT	Hollenberg, et al. "Primary Structure and Expression of a Functional Human Glucocorticoid Receptor cDNA" Nature International Weekly Journal of Science (1985) Vol. 318, No. 6047, pp. 635-641
CU	Katz M., et al. "Scholtz-Dumas psoriasis small plaque bioassay" Journal of Dermatological Treatment (2000) Vol. 11, pp. 15-19
CV	Katz M., et al. "Corticoid, Vehicle, and Skin Interaction in Percutaneous Absorption" Journal of the Society of Cosmetic Chemists (1972) Vol. 23, No. 9, pp. 565-590
CW	Katz, et al. "Percutaneous Corticosteroid Absorption Correlated to Partition Coefficient" Journal of Pharmaceutical Sciences (1965) Vol. 54, No. 4, pp. 591-594
CX	Katz, et al. "Absorption of Drugs through the Skin" Handbook of experimental Pharmacology (1971) Vol. 28, Part 1, pp. 104-162
CY	Kendall, E.C. "Arthritis" Cortisone (1971), pp. 121-137
CZ	McKenzie, et al. "Method for Comparing Percutaneous Absorption of Steroids" Archives of Dermatology (1962) Vol. 86, pp. 88-90
DA	Murphy W.B. "A Half Century of Innovation at Syntex" Science Serendipity (1994)
DB	Murray, J.R. "The History of Corticosteroids" Updates in Dermatology (1989) Vol. 69, Suppl. 151, pp. 4-6
DC	Ostrega, et al. "Vehicle Design for a new Topical Steroid, Fluodinonide" The Journal of Investigative Dermatology (1971) Vol. 56, No. 5, pp. 392-399

	DE	Place, et al. "Precise Evaluation of Topically Applied Corticosteroid Potency" Archives of Dermatology (1970) Vol. 101, No. 5, pp. 531-537
	DF	Ponec M. "Glucocorticoid Receptors", Topical Glucocorticoids with Increased Benefit/Risk Ratio (1993) Vol. 21, pp. 20-28
	DG	Ponec, M. "Effects of Glucocorticoids on Cultured Skin Fibroblasts and Keratinocytes" International Journal of Dermatology (1984) Vol. 23, No. 1, pp. 11-24
	DH	Reinstein, et al. "Design of the Optimal Topical System for Fluocinonide" Acta Dermato-Venereologica (1971) Vol. 52, Suppl. 67, pp. 13-18
	DI	Rhen, et al. "Antiinflammatory Action of Glucocorticoids – New Mechanisms for Old Drugs" The New England Journal of Medicine (2005) Vol. 353, pp. 1711-1723
	DJ	Ringold, et al. "Steroids. LXXV. Dehydrogenation of Testosterone to $\Delta^{1,4}$ -Androstadien-17 β -ol-3-one with Selenium Dioxide" The Journal of Organic Chemistry (1956) Vol. 21, No. 2, pp. 239-240
	DK	Rosenkranz, G. "The Early Days of Syntex" (2005), pp. 10-12
	DL	Scholtz, J.R. "Topical Therapy of Psoriasis with Fluocinolone Acetonide" Archives Dermatology, (1961) Vol. 84, pp. 191-192
	DM	Stouch, T.R. "Structure-Activity Relationships using Multivariate Analysis Techniques: Application to Topical Corticosteroids, Maibach HI, Surber C (1992) pp. 93-127
	DN	Stoughton, R.B. "Vasoconstrictor Assay – Specific Applications" Topical Corticosteroids (1992), pp. 42-53
	DO	Sulzberger, et al. "The Effect of Topically Applied Compound F in selected Dermatoses" The Journal of Investigative Dermatology (1952) Vol. 19, pp. 101-102
	DP	Syntex: A Corporation and a Molecule: The Story of Research at Syntex (1966)
	DQ	Wieland, et al. "Ester der Nebennierenrinden-Hormone mit Protrahierter Wirkung" (1951) pp 354-358
	DR	Wolff, M.E. "Structure-Activity Relationships in Glucocorticoids" Glucocorticoid Hormone Action (1979), Chapter 5, pp. 97-107
	DS	Zhou, et al. "The Human Glucocorticoid Receptor: One Gene, Multiple Proteins and Diverse Responses" Steroids (2005) Vol. 70, pp. 407-417
EXAMINER		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.